How are CYP2D6 and blood sugar related?

The provided knowledge context contains no direct information linking CYP2D6 to blood sugar. CYP2D6 is primarily a drug-metabolizing enzyme; its variants affect how quickly certain medications (e.g., beta-blockers, antidepressants) are cleared. Some of these drugs can alter glucose levels, but that is a pharmacological, not a direct genetic, effect. In nutrigenetics and precision health, there is no robust evidence that CYP2D6 polymorphisms meaningfully impact fasting glucose or diabetes risk. Most studies are small or inconsistent. A consumer genetic test for CYP2D6 is therefore not actionable for blood sugar management. Clinically relevant factors include insulin resistance, lifestyle, and genes like TCF7L2 or GCK. Evidence grade: unclear, as no validated data from the context support a direct relationship.